Background: Chylous ascites is rare, accounting for less than 1% of cases. An appropriate and stepwise approach to its diagnosis and management is of key importance.
| INTRODUCTION
Chylous ascites is defined as a milky appearing, triglyceride-rich peritoneal fluid, characterised by the presence of thoracic or intestinal lymph in the abdominal cavity. 1 Abdominal malignancy, cirrhosis, lymphatic disruption after abdominal surgery, and infections represent the leading causes in adults. 2 In children, congenital lymphatic abnormalities and trauma are considered the most common etiologies. 3 Its incidence is not well established, however, previous data from Press et al published in 1984 indicates that it accounts for 1 per 20 000 hospital admissions overall, since then no further epidemiological studies have been performed, thus the current incidence is not well known. 4 Chylous ascites is rich in nutrients and immunoglobulins, which become no longer biologically available after accumulating in the peritoneum. This can lead to dehydration, malnutrition, electrolyte imbalance and immunosuppression. 5 Therefore, prompt diagnosis and treatment is warranted.
Herein, we review best practices for diagnosis and conservative treatment as well as emerging therapeutic options for refractory cases of chylous ascites.
| ME TH ODS
A literature search was conducted using PubMed using the key words 'chylous', 'ascites', 'cirrhosis', 'pathophysiology', 'nutritional therapy', 'paracentesis" and "TIPSS'. Only articles in English were included.
| Pathophysiology
The underlying cause of chylous ascites is the disruption of lymphatic flow. An interconnected network moves lymph-a complex mixture of proteins, lipids/chylomicra, and immune cells-from the body to the thoracic duct where it empties into the venous circulation at the union of the left internal jugular vein and the subclavian vein. Lymph is propelled through its circuit by the active, intrinsic contraction/relaxation of lymphatic vessels and passive, external compressive forces (skeletal muscles, central venous pressure variations, respiratory movement and pulsations of adjacent arteries). 6 Approximately half of the lymph originates in the intestine. After hydrolysis and emulsification, fatty acids and monoglycerides are converted into triglycerides, which are subsequently absorbed into the lymphatic system as chylomicrons. Hence, the milky appearance of the lymph is attributed to its high triglyceride and free fatty acid content.
Browse et al 7 proposed three pathophysiologic mechanisms by which chylous ascites occurs (Table 1) : acquired lymphatic disruption, fibrosis of the lymphatic system and congenital causes.
Acquired lymphatic disruption from surgery or trauma, leads to dilation of the retroperitoneal lymphatics with subsequent drainage of lymph into the abdomen through a lymphoperitoneal fistula. This dilation of lymphatic vessels also occurs as a result of the increased lymph production and elevated hepatic venous pressure seen in patients with cirrhosis and constrictive pericarditis. Cardiac conditions such as right heart failure and dilated cardiomyopathy lead to an increased lymphatic pressure from disrupted lymphatic drainage, thereby causing lymph stasis, lymphatic dilation and chylous ascites.
The caval and hepatic venous hypertension precipitates an increment in the production of hepatic lymph. 8 The second proposed mechanism is lymph node fibrosis, most commonly due to malignancy causing lymph flow obstruction from the gut into the cysterna chyli, resulting in leakage from the dilated subserosal lymphatics into the peritoneum. The chronic effects of a persistently elevated lymphatic pressure may lead to collagen deposition at the basement membrane of the lymphatics, impairing the intestinal mucosal absorptive capacity. This process can cause protein-losing enteropathy with malabsorption, chronic steatorrhea and malnutrition. Last, congenital causes like congenital lymphangiectasia lead to exudation and leakage of lymph through a fistula into the peritoneal cavity due to the absence of lymphatic valves.
| Etiologies
Multiple etiologies have been described as causes of chylous ascites.
Traditionally, the most common causes in western countries are abdominal malignancy and cirrhosis, accounting for two-thirds of atraumatic chylous ascites cases. 4 In developing and eastern coun- | 817 frequent etiology (7%). Cirrhosis and mycobacterial infections were identified in 11% and 10% of the cases respectively.
| Malignancy
Malignancy causes chylous ascites through the invasion and disruption of the normal lymph flow. 7 The most common malignancies reported to cause chylous ascites are lymphomas, neuroendocrine tumors, sarcomas (Kaposi sarcoma) and leukemias (chronic lymphatic leukemias) in order of prevalence. 3 Among the group of the abovementioned malignancies, lymphoma accounts for at least one-third of the cases 3 Solid malignancies can also cause chylous ascites.
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| Cirrhosis
Only 0.5%-1% of all cases of cirrhosis-related ascites are chylous in nature. 8, 11 Runyon et al 12 analyzed a total of 901 ascites samples where eleven were chylous ascites; 10 of them were found to be secondary to cirrhosis and one due to malignancy. The underlying etiology is unclear but may be related to excessive hepatic and gastrointestinal lymph flow (up to 20 L/day) secondary to portal hypertension, leading to spontaneous rupture of the serosal lymphatic channels. Although data is limited, transjugular intrahepatic portosystemic shunt has proven effective for cases of refractory chylous ascites. 13, 14 The decompression of the portal vein has shown to relieve lymphatic hypertension. 
| Congenital
The congenital causes of chylous ascites are more commonly seen in the paediatric population. Steinemann et al found lymphangiectasia as the most common cause of congenital anomaly in children (84%).
| Other causes
Other less common causes include cardiac conditions, nephrotic syndrome, pancreatitis, coeliac sprue, Whipple's disease and retractile mesenteritis. [42] [43] [44] [45] [46] [47] Cardiac disease with increased right-venous pressures can lead to increased hepatic lymph production; causing impaired drainage, chyle stasis, lymphatic dilation and ultimately chylous ascites. [48] [49] [50] These include right heart failure, dilated cardiomyopathy and constrictive pericarditis. Chen et al, 51 reported a case of chylous ascites secondary to cardiac amyloidosis, where the contributing factor was thought to be increased left subclavian venous pressure. Both acute necrotizing pancreatitis and chronic pancreatitis are associated with chylous ascites; the underlying mechanism remains unknown but is thought to be due to direct compression of lymphatic channels.
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| Evaluation and diagnosis
The clinical evaluation of a patient that presents with ascites should start with a thorough history and physical examination. The total protein content ranges between 2.5 and 7.0 g/dL and will vary according to the underlying etiology. 12 Typically, hepatic cirrhosis is associated with a total protein concentration in the ascites of less than 2.5 g/dL. In addition, the serum to ascites albumin gradient can be used to identify the presence of portal hypertension in the setting of liver-related disease. 57 A serum to ascites albumin gradient below 1.1 g/dL rules out portal hypertension and suggests other etiologies. In patients with chylous ascites secondary to cirrhosis, the serum to ascites albumin gradient is normally above 1.1 g/dL.
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Interestingly, CA-125 has been reported to be particularly elevated in cirrhotic patients with chylous ascites (Figure 2 ). Table 2 ).
The key initial step in management of chylous ascites is to optimise the patient's nutritional status. Nutritional support includes a high-protein, low fat diet supplemented with medium-chain triglycerides. 64 Medium-chain triglycerides are absorbed by the enterocytes and transported as free fatty acids and glycerol directly into the liver through the portal vein, sparing the lymphatic system. This is in contrast to long-chained triglycerides, which are converted to free fatty acids and monoglycerides that are then transported as chylomicrons 
Chylous ascites differential diagnosis algorithm. *Peritoneal causes: consider malignancy, inflammatory or infectious causes. SAAG, serum to ascites albumin gradient; ADA, adenosine deaminase; TB, tuberculosis to the intestinal lymph ducts contributing to the overall lymphatic pool. Capric, caprylic and lauric acid are medium-chain triglycerides found in coconut oil, palm kernel oil, whole milk, butter and cheese.
Most oils and fats, including nuts, fish, meat, olive oil and avocado contain long-chained triglycerides and should be avoided in chylous ascites. 65 Orlistat, a gastric and pancreatic lipase inhibitor, has shown to reduce the triglyceride concentration in ascites and can be used adjunctively to a low-fat diet with medium-chain triglycerides, although data is limited. 66 Somatostatin, or its synthetic analogue, octreotide, have been used as well in the treatment of chylous ascites. 67 The exact mechanism of action of somatostatin or its analogue is not completely understood. However, it has shown to decrease portal pressure by inhibiting glucagon and other intestinal peptide-mediated splanchnic vasodilatation. It also diminishes peristalsis, intestinal absorption of fats, triglyceride concentration in the thoracic duct and attenuates the lymph flow in the major channels. 68 Somatostatin must be administered intravenously due to its short half-life of 1-3 minutes.
Octreotide has a longer half-life of 2 hours and the advantage of subcutaneous administration. This somatostatin analogue has successfully been used in patients with chylous ascites secondary to pancreatitis, malignancy, post-liver transplant, portal vein thrombosis and idiopathic cases. 69, 70 Berzigotti et al, 68 utilised it as a long-term medication during 6 months in a patient with refractory chylous ascites in the setting of cirrhosis with no relapses after discontinuation. In addition to nutrition and somatostatin analogues, total parenteral nutrition (TPN) can be considered if other measures fail.
However, emerging data has found enteral nutrition with mediumchain triglycerides superior to TPN. 71 Therapeutic paracentesis may be performed to provide temporary symptomatic relief. Repetitive drainage should be avoided as it can lead to electrolyte imbalance, malnutrition and infection. 73 Intravascular volume and albumin replacement to prevent post-paracentesis circulatory derangements is not necessary unless the patient has underlying cirrhosis.
The management of cirrhosis-related chylous ascites involves a stepwise management approach. Initially, treatment is centered on the use of diuretics and nutritional optimization with a low sodium, low fat, and high protein diet with medium-chain triglycerides. In patients who are refractory to medical therapy and maintain normal liver function, transjugular intrahepatic portosystemic shunt can be considered to help reduce portal pressures, although the data is limited. 13, 74 Even though the effects of transjugular intrahepatic portosystemic shunt on chylous ascites are still preliminary, it is believed that portal decompression reduces the flow of lymph and reduces the formation of chylous ascites. 14 The recurrence of symptoms after shunt dysfunction supports this theory. 13 Nonetheless, the benefit of transjugular intrahepatic portosystemic shunt placements should be weighed with its inherent risks.
A number of additional therapeutic strategies have been trialed for refractory chylous ascites including glue embolization, splenorenal shunt, surgical ligation and embolization of disrupted lymphatic channels, but the data is preliminary. [75] [76] [77] Peritoneovenous shunting was used in the past, however, it is rarely performed nowadays due to its high morbidity from sepsis, electrolyte imbalance, disseminated intravascular coagulopathy, small bowel obstruction and air Other therapies such as glue embolization, spleno-renal shunt, surgical ligation and embolization of disrupted lymphatic channels are not recommended due to preliminary data. Peritoneovenous shunting is no longer used due to high morbidity from adverse effects.
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There is not sufficient data for these interventions.
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| 821 embolism. 78 Despite the number of potential therapeutic options available for chylous ascites, conservative treatment remains the cornerstone of therapy in these patients until further data emerges.
| CONCLUSIONS
Chylous ascites is an uncommon disorder characterised by the presence of a milky-appearing, triglyceride-rich fluid in the peritoneum.
It is caused by the disruption of the lymphatic system with subse- 
